Caxton Associates LLP Xeris Biopharma Holdings, Inc. Transaction History
Caxton Associates LLP
- $4.11 Billion
- Q3 2025
A detailed history of Caxton Associates LLP transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 281,337 shares of XERS stock, worth $2.04 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
281,337Holding current value
$2.04 Million% of portfolio
0.06%Shares
2 transactions
Others Institutions Holding XERS
# of Institutions
237Shares Held
94.1MCall Options Held
251KPut Options Held
61.8K-
Black Rock Inc. New York, NY10.3MShares$74.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.83MShares$71.3 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.84MShares$42.3 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA4.14MShares$30 Million0.0% of portfolio
-
State Street Corp Boston, MA3.74MShares$27.1 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $986M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...